Pharmaceuticals, Biotechnology and Life Sciences
Novartis’s division Sandoz, and Pear Therapeutics, have launched reSET for patients with Substance Use Disorder (SUD), which is th efirst…
Indivior PLC said Wednesday said in a statement it is dissapointed by the US District Court for the District of…
Swedish Oasmia Pharmaceutical said on Tuesday that it got a patent for its unique nanotech method to produce novel pharmaceutical formulations, from the United States Patent and Trademark Office (USPTO).
Denali Therapeutics, a neurodegenerative diseases specialist, on Tuesday brought to public positive results from its Phase 1 healthy volunteer study of DNL747, a brain penetrant small molecule inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1),
SkinBioTherapeutics has begun the final phases of its human study of SkinBiotix, to ensure that the original technology retains the same…
A T Cell Receptor (TCR) biotechnology specialist Immunocore Limited, has entered into a new partnership with Genentech, a member of…
Basilea Pharmaceutica will presenting its new preclinical data on its clinical stage anticancer drug candidate BAL101553 at the 30 EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland.
The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the @Regeneron Pharmaceuticals and Sanofi made supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) in adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis, whose disease was inadequately controlled with topical therapies or for whom topical treatment was medically inadvisable.
Illumina will acquire Pacific Biosciences for $1.2 billion, it was revealed on Friday, after the agreement had been approved by the board of directors of Illumina and Pacific Biosciences.
$ILMN $PACB
Denali Therapeutics will work with Sanofi on its multiple RIPK1 inhibitor molecules that could treat a range of neurological and systemic inflammatory diseases.